Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ALN-4915 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| ALN-4915 | EXPERIMENTAL | Participants will be administered a single dose of ALN-4195. |
| Placebo | PLACEBO_COMPARATOR | Participants will be administered a single dose of placebo. |
| Name | Type | Description |
|---|---|---|
| ALN-4915 | DRUG | ALN-4915 will be administered subcutaneously (SC) |
| Placebo | DRUG | Placebo will be administered SC |
Inclusion Criteria: * Is willing and able to complete all study assessments Exclusion Criteria: * Has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>upper limit of normal (ULN) * Has total bilirubin \>ULN * Has no history of invasive infection by an encapsulated organism * H...
ALN-4915 is an investigational drug being studied in adult healthy volunteers. It is currently in Phase 1 clinical development, with an ongoing trial evaluating its safety and tolerability in this population. The drug is being developed by Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY).
ALN-4915 is being developed by Alnylam Pharmaceuticals, Inc., a biopharmaceutical company traded on NASDAQ under the ticker ALNY. The company is currently conducting a Phase 1 clinical trial of ALN-4915 in healthy volunteers.
ALN-4915 is in Phase 1 clinical development. The drug is investigational and has not been approved by regulatory authorities. A Phase 1 study is currently recruiting participants to evaluate the drug in adult healthy volunteers.
ALN-4915 is being evaluated in a Phase 1 clinical trial with the identifier NCT07535606, titled "A Study to Evaluate ALN-4915 in Adult Healthy Volunteers." This randomized, double-blind, placebo-controlled study is recruiting 44 participants in the United Kingdom.
No alternative names for ALN-4915 have been disclosed. The drug is identified solely by its development code ALN-4915 in the ongoing clinical trial. It is an investigational compound being studied by Alnylam Pharmaceuticals.